EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed‐methods study

Maria Mainou, Thomas Karagiannis, Eirini Pagkalidou, Aris Liakos, Panagiotis Malandrakis, Evdoxia Hatjiharissi, Sofia Chissan, Evdokia Mandala iD, Oliver Van Oekelen, Efthymia Vlachaki, Maria Papaioannou, Evangelos Terpos und 2 weitere

British Journal of Haematology · 2026-05 · 208 (5) · 1650-1659

DOI: 10.1111/bjh.70396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 26.02.2026. Verfasst von Maria Mainou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Hippokration General Hospital, T…. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research in multiple myeloma increasingly relies on surrogate end‐points to expedite approvals, yet these may not reflect patient priorities. We conducted a mixed‐methods study to identify outcomes valued by patients and clinicians and compare them with end‐points used in randomized controlled trials (RCTs). Interviews with 10 patients and 6 clinicians identified treatment priorities, which, together with end‐points from a systematic review of myeloma RCTs, informed tailored surveys, completed by 117 patients and 105 clinicians. Both groups ranked quality of life (QoL) as most important (odds ratio [OR] 1.01; 95% confidence interval [CI] 0.55–1.87). Clinicians more often prioritized overall survival (OS) (OR 1.92; 95% CI 1.05–3.50) and progression‐free survival (PFS) (OR 5.37; 95% CI 1.95–14.79), whereas patients prioritized pain reduction (OR 0.03; 95% CI 0.00–0.23). Compared with RCT end‐points, patients emphasized QoL (OR 0.03; 95% CI 0.01–0.07) and pain elimination (OR 0.05; 95% CI 0.02–0.11), while trials favoured PFS (OR 6.33; 95% CI 2.53–15.83) and response (OR 17.75; 95% CI 5.56–56.61). Clinicians aligned with trials on PFS but valued QoL and OS more highly. QoL emerged as a shared priority, underscoring the need for patient‐centred trial designs that better capture outcomes meaningful to those living with myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaQuality of LifeHumansFemaleMaleAgedMiddle AgedRandomized Controlled Trials as TopicTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

mixed‐methods researchmultiple myelomaoutcomes

Autor:innen und Institutionen

  • Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.
  • Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Hematology Unit, First Department of Internal Medicine, AHEPA General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.
  • Fourth Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.

ORCID-Profile: Evdokia Mandala, Ghulam Rehman Mohyuddin

Zitieren

APA

Mainou, M., Karagiannis, T., Pagkalidou, E., Liakos, A., Malandrakis, P., Hatjiharissi, E., Chissan, S., Mandala, E., Van Oekelen, O., Vlachaki, E., Papaioannou, M., Terpos, E., Mohyuddin, G. R., & Tsapas, A. (2026). Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed‐methods study. British Journal of Haematology, 208(5), 1650-1659. https://doi.org/10.1111/bjh.70396

Vancouver

Mainou M, Karagiannis T, Pagkalidou E, Liakos A, Malandrakis P, Hatjiharissi E, et al. Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed‐methods study. British Journal of Haematology. 2026;208(5):1650-1659. doi:10.1111/bjh.70396

BibTeX
@article{Mainou2026,
  author = {Mainou, Maria and Karagiannis, Thomas and Pagkalidou, Eirini and Liakos, Aris and Malandrakis, Panagiotis and Hatjiharissi, Evdoxia and Chissan, Sofia and Mandala, Evdokia and Van Oekelen, Oliver and Vlachaki, Efthymia and Papaioannou, Maria and Terpos, Evangelos and Mohyuddin, Ghulam Rehman and Tsapas, Apostolos},
  title = {Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed‐methods study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {5},
  pages = {1650--1659},
  doi = {10.1111/bjh.70396}
}
Kostenlos starten →